vs
Side-by-side financial comparison of GoodRx Holdings, Inc. (GDRX) and QuidelOrtho Corp (QDEL), based on the latest 10-Q / 10-K filings. Click either name above to swap in a different company.
QuidelOrtho Corp is the larger business by last-quarter revenue ($699.9M vs $194.8M, roughly 3.6× GoodRx Holdings, Inc.). GoodRx Holdings, Inc. runs the higher net margin — 2.8% vs -104.7%, a 107.5% gap on every dollar of revenue. On growth, GoodRx Holdings, Inc. posted the faster year-over-year revenue change (-1.9% vs -3.7%). GoodRx Holdings, Inc. produced more free cash flow last quarter ($31.6M vs $-94.7M). Over the past eight quarters, GoodRx Holdings, Inc.'s revenue compounded faster (-0.8% CAGR vs -2.9%).
GoodRx Holdings, Inc. is an American healthcare company that operates a telemedicine platform and free-to-use website and mobile app that track prescription drug prices in the United States and provide drug coupons for discounts on medications. GoodRx compares prescription drug prices at more than 75,000 pharmacies in the United States. The platform allows users to consult a doctor online and obtain a prescription for certain types of medications.
QuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products that are sold worldwide.
GDRX vs QDEL — Head-to-Head
Income Statement — Q4 2025 vs Q3 2026
| Metric | | |
|---|---|---|
| Revenue | $194.8M | $699.9M |
| Net Profit | $5.4M | $-733.0M |
| Gross Margin | — | — |
| Operating Margin | 11.6% | -100.7% |
| Net Margin | 2.8% | -104.7% |
| Revenue YoY | -1.9% | -3.7% |
| Net Profit YoY | -19.5% | -3583.4% |
| EPS (diluted) | $0.02 | $-10.78 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align — see 8-quarter trend below.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history — bar widths are scaled to the larger of the two companies so you can eyeball the size gap and growth trajectory without doing math. Quarters aligned by calendar period (report date) so offset fiscal years line up.
| Q4 25 | $194.8M | — | ||
| Q3 25 | $196.0M | $699.9M | ||
| Q2 25 | $203.1M | $613.9M | ||
| Q1 25 | $203.0M | $692.8M | ||
| Q4 24 | $198.6M | $707.8M | ||
| Q3 24 | $195.3M | $727.1M | ||
| Q2 24 | $200.6M | $637.0M | ||
| Q1 24 | $197.9M | $711.0M |
| Q4 25 | $5.4M | — | ||
| Q3 25 | $1.1M | $-733.0M | ||
| Q2 25 | $12.8M | $-255.4M | ||
| Q1 25 | $11.1M | $-12.7M | ||
| Q4 24 | $6.7M | $-178.4M | ||
| Q3 24 | $4.0M | $-19.9M | ||
| Q2 24 | $6.7M | $-147.7M | ||
| Q1 24 | $-1.0M | $-1.7B |
| Q4 25 | 11.6% | — | ||
| Q3 25 | 7.5% | -100.7% | ||
| Q2 25 | 13.2% | -29.4% | ||
| Q1 25 | 11.5% | 4.7% | ||
| Q4 24 | 9.2% | -14.2% | ||
| Q3 24 | 10.5% | 2.1% | ||
| Q2 24 | 9.9% | -18.4% | ||
| Q1 24 | 3.7% | -247.3% |
| Q4 25 | 2.8% | — | ||
| Q3 25 | 0.6% | -104.7% | ||
| Q2 25 | 6.3% | -41.6% | ||
| Q1 25 | 5.4% | -1.8% | ||
| Q4 24 | 3.4% | -25.2% | ||
| Q3 24 | 2.0% | -2.7% | ||
| Q2 24 | 3.3% | -23.2% | ||
| Q1 24 | -0.5% | -239.9% |
| Q4 25 | $0.02 | — | ||
| Q3 25 | $0.00 | $-10.78 | ||
| Q2 25 | $0.04 | $-3.77 | ||
| Q1 25 | $0.03 | $-0.19 | ||
| Q4 24 | $0.01 | $-2.54 | ||
| Q3 24 | $0.01 | $-0.30 | ||
| Q2 24 | $0.02 | $-2.20 | ||
| Q1 24 | $0.00 | $-25.50 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest filing — the kind of financial-strength check premium terminals charge for.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $261.8M | $98.1M |
| Total DebtLower is stronger | $495.0M | $2.5B |
| Stockholders' EquityBook value | $616.3M | $2.0B |
| Total Assets | $1.4B | $5.7B |
| Debt / EquityLower = less leverage | 0.80× | 1.23× |
8-quarter trend — quarters aligned by calendar period so offset fiscal years match up.
| Q4 25 | $261.8M | — | ||
| Q3 25 | $273.5M | $98.1M | ||
| Q2 25 | $281.3M | $151.7M | ||
| Q1 25 | $301.0M | $127.1M | ||
| Q4 24 | $448.3M | $98.3M | ||
| Q3 24 | $423.8M | $143.7M | ||
| Q2 24 | $524.9M | $107.0M | ||
| Q1 24 | $533.3M | $78.5M |
| Q4 25 | $495.0M | — | ||
| Q3 25 | — | $2.5B | ||
| Q2 25 | — | $2.1B | ||
| Q1 25 | — | $2.1B | ||
| Q4 24 | $500.0M | $2.1B | ||
| Q3 24 | — | $2.2B | ||
| Q2 24 | — | $2.2B | ||
| Q1 24 | — | $2.2B |
| Q4 25 | $616.3M | — | ||
| Q3 25 | $600.7M | $2.0B | ||
| Q2 25 | $643.0M | $2.8B | ||
| Q1 25 | $654.3M | $3.0B | ||
| Q4 24 | $724.7M | $3.0B | ||
| Q3 24 | $696.4M | $3.2B | ||
| Q2 24 | $669.4M | $3.2B | ||
| Q1 24 | $631.1M | $3.3B |
| Q4 25 | $1.4B | — | ||
| Q3 25 | $1.3B | $5.7B | ||
| Q2 25 | $1.3B | $6.4B | ||
| Q1 25 | $1.3B | $6.5B | ||
| Q4 24 | $1.4B | $6.4B | ||
| Q3 24 | $1.4B | $6.8B | ||
| Q2 24 | $1.5B | $6.7B | ||
| Q1 24 | $1.5B | $6.7B |
| Q4 25 | 0.80× | — | ||
| Q3 25 | — | 1.23× | ||
| Q2 25 | — | 0.74× | ||
| Q1 25 | — | 0.70× | ||
| Q4 24 | 0.69× | 0.72× | ||
| Q3 24 | — | 0.68× | ||
| Q2 24 | — | 0.70× | ||
| Q1 24 | — | 0.68× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Net income can be massaged; cash flow is harder to fake.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $-45.5M |
| Free Cash FlowOCF − Capex | $31.6M | $-94.7M |
| FCF MarginFCF / Revenue | 16.2% | -13.5% |
| Capex IntensityCapex / Revenue; lower = less reinvestment burden | 0.6% | 7.0% |
| Cash ConversionOCF / Net Profit; >1× = earnings back up with cash | 6.06× | — |
| TTM Free Cash FlowTrailing 4 quarters | $164.4M | $-153.1M |
8-quarter trend — quarters aligned by calendar period so offset fiscal years match up.
| Q4 25 | $32.9M | — | ||
| Q3 25 | $76.0M | $-45.5M | ||
| Q2 25 | $49.6M | $-46.8M | ||
| Q1 25 | $9.4M | $65.6M | ||
| Q4 24 | $44.7M | $63.7M | ||
| Q3 24 | $86.9M | $117.9M | ||
| Q2 24 | $9.7M | $-97.9M | ||
| Q1 24 | $42.6M | $-700.0K |
| Q4 25 | $31.6M | — | ||
| Q3 25 | $74.3M | $-94.7M | ||
| Q2 25 | $49.2M | $-84.3M | ||
| Q1 25 | $9.3M | $9.4M | ||
| Q4 24 | $44.6M | $16.5M | ||
| Q3 24 | $86.5M | $71.4M | ||
| Q2 24 | $9.4M | $-133.2M | ||
| Q1 24 | $42.2M | $-66.8M |
| Q4 25 | 16.2% | — | ||
| Q3 25 | 37.9% | -13.5% | ||
| Q2 25 | 24.2% | -13.7% | ||
| Q1 25 | 4.6% | 1.4% | ||
| Q4 24 | 22.4% | 2.3% | ||
| Q3 24 | 44.3% | 9.8% | ||
| Q2 24 | 4.7% | -20.9% | ||
| Q1 24 | 21.3% | -9.4% |
| Q4 25 | 0.6% | — | ||
| Q3 25 | 0.9% | 7.0% | ||
| Q2 25 | 0.2% | 6.1% | ||
| Q1 25 | 0.1% | 8.1% | ||
| Q4 24 | 0.1% | 6.7% | ||
| Q3 24 | 0.2% | 6.4% | ||
| Q2 24 | 0.1% | 5.5% | ||
| Q1 24 | 0.2% | 9.3% |
| Q4 25 | 6.06× | — | ||
| Q3 25 | 67.94× | — | ||
| Q2 25 | 3.86× | — | ||
| Q1 25 | 0.85× | — | ||
| Q4 24 | 6.64× | — | ||
| Q3 24 | 21.91× | — | ||
| Q2 24 | 1.45× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Sankey diagram of revenue → gross profit → operating profit → net profit for each company. Charts shown full-width and stacked so both segment hierarchies are readable side-by-side on desktop and mobile.
Revenue Breakdown by Segment
GDRX
| Prescription Transactions Revenue | $124.7M | 64% |
| Other | $44.4M | 23% |
| Subscription Revenue | $21.6M | 11% |
| Other Revenue | $4.1M | 2% |
QDEL
| Labs | $373.8M | 53% |
| Point Of Care | $164.6M | 24% |
| Immunohematology | $142.0M | 20% |
| Donor Screening | $14.7M | 2% |
| Molecular Diagnostics | $4.8M | 1% |
| Collaborative Arrangement Transaction With Party To Collaborative Arrangement | $2.1M | 0% |
